Company research
BriaCell Therapeutics Corp.
CIK 1610820Updated Sep 25, 2026
SecuritiesBCTX · NASDAQ · equityBCT · TSX · equityBCTXL · NASDAQ · warrantBCTXZ · NASDAQ · warrant
Historical securities (1)
BCTXW · NASDAQ · warrant · closed Feb 26, 2026Name history
Ansell Capital Corp. · through Jun 20, 2014
BCTX price & chart
Loading TradingView…
NASDAQ:BCTX on TradingView ↗About the company
BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and destroy cancer cells. The Company is currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. Bria-IMT™ is currently under Fast Track Designation by the U.S. Food and Drug Administration (the “FDA”) intended to accelerate the review process of novel treatments that address unmet medical needs. Positive completion of the pivotal study, following review by FDA, could lead to full approval of the Bria-IMT™ immune checkpoint inhibitor combination in metastatic breast cancer. BriaCell reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.4 months in BriaCell’s metastatic breast cancer patients vs. 6.7-9.8 months for similar patients reported in the literature in its Phase 2 study of Bria-IMT™ combin…
In the news
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Other Events
Items 1.01, 3.02, 8.01, 9.01
424B5 filing
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 21,649,706Source | 5,872,261Source | 27,163,577Source | 42,577,041Source |
| Property, Plant and Equipment, NetUSD | 296,819Source | 388,175Source | 2,500Source | 2,500Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 184,525Source | 199,796Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,493,808Source | 862,089Source | 21,251,092Source | 41,041,652Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 18,873Source | 24,103Source |
| Assets, CurrentUSD | 19,926,576Source | 3,653,854Source | 26,948,507Source | 42,346,700Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 101,739,923Source | 72,166,414Source | 69,591,784Source | 65,589,293Source |
| Retained Earnings (Accumulated Deficit)USD | -111,755,564Source | -85,443,697Source | -80,652,231Source | -60,349,837Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -138,684Source | -138,684Source | -138,684Source | -138,684Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | -3,777,181Source | 10,328,932Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 5,228,160Source |
| Liabilities and EquityUSD | 21,649,706Source | 5,872,261Source | 27,163,577Source | 42,577,041Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,977,988Source | 7,461,157Source | 1,801,457Source | 941,087Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -546,795Source | -302,522Source | — | — |
| Additional Financial Items | ||||
| Short-term InvestmentsUSD | 7,372,473Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -26,556,140Source | -4,931,548Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 15,272Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 776,879Source | 1,804,078Source | 2,193,790Source | 3,074,584Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -733,629Source | 732,578Source | -5,230Source | 11,530Source |
| Increase (Decrease) in Accounts PayableUSD | -3,887,078Source | 6,047,042Source | 660,459Source | 249,164Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -28,170,520Source | -24,126,128Source | -23,744,860Source | -12,484,376Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -7,646,000Source | -681,801Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 456,801Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 45,448,239Source | 4,418,926Source | 3,954,300Source | -3,742,657Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 9,631,719Source | -20,389,003Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,493,808Source | 862,089Source | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | 15,271Source | 15,271Source | 15,271Source | — |
| Amortization of Intangible AssetsUSD | 15,271Source | 15,271Source | 15,271Source | 15,271Source |
| DepreciationUSD | 91,356Source | 68,626Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -24,941Source | -25,452Source | -40,873Source | -30,730Source |
| General and Administrative ExpenseUSD | 5,934,125Source | 6,152,269Source | 7,935,626Source | 7,267,452Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | -224,212Source | -106,510Source | — | — |
| InterestExpenseNonoperatingUSD | 36,979Source | — | — | — |
| Investment Income, InterestUSD | 119,958Source | 288,018Source | 891,213Source | 136,731Source |
| Net Income (Loss) Attributable to ParentUSD | -26,311,867Source | -4,791,466Source | -20,302,394Source | -26,838,903Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -244,273Source | -140,082Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,311,867Source | -4,931,548Source | -20,302,394Source | -26,838,903Source |
| Nonoperating Income (Expense)USD | 114,511Source | 262,566Source | 2,969,870Source | -11,549,962Source |
| Operating ExpensesUSD | 27,204,803Source | 33,330,076Source | — | — |
| Payments to Acquire InvestmentsUSD | 330,000Source | 225,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 44,627,224Source | 4,418,926Source | 4,000,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 56,473Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -27,204,803Source | -33,330,076Source | -23,272,264Source | -15,288,941Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 26,556,140Source | 4,931,548Source | -20,302,394Source | -26,838,903Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -244,273Source | -140,082Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -26,311,867Source | -4,791,466Source | -20,302,394Source | -26,838,903Source |
| Earnings Per Share, BasicUSD per share | -62.19Source | -0.29Source | -1.3Source | -1.73Source |
| Earnings Per Share, DilutedUSD per share | -62.19Source | -0.29Source | -1.3Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 423,114Source | 16,454,932Source | 15,619,676Source | 15,494,091Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 423,114Source | 16,454,932Source | 15,619,676Source | — |
| Interest Expense (non-operating)USD | 36,979Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 15,271Source | 15,271Source | 15,271Source | 15,271Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -24,941Source | -25,452Source | -40,873Source | -30,730Source |
| General and Administrative ExpenseUSD | 5,934,125Source | 6,152,269Source | 7,935,626Source | 7,267,452Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 23,999,920Source | -23,946,952Source | 2,469,999Source | -16,551,241Source |
| Income (Loss) from Equity Method InvestmentsUSD | -224,212Source | -106,510Source | — | — |
| Interest ExpenseUSD | — | — | — | 979Source |
| Investment Income, InterestUSD | 119,958Source | 288,018Source | 891,213Source | 136,731Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -26,311,867Source | -4,931,548Source | -20,302,394Source | -26,838,903Source |
| Nonoperating Income (Expense)USD | 114,511Source | 262,566Source | 2,969,870Source | -11,549,962Source |
| Operating ExpensesUSD | 27,204,803Source | 33,330,076Source | — | — |
| Research and Development ExpenseUSD | 21,270,678Source | 27,177,807Source | 15,336,638Source | 8,021,489Source |
Offerings
Registration 333-292388
- Gross proceeds
- 29998959.0
- Net proceeds
- 28123959.0
- Deal price
- 5.59
- Shares
- 5366540
- Offering price
- $5.59
- Ticker
- BCTXL
Registration 333-288562
- Gross proceeds
- 14998775.0
- Net proceeds
- 13873775.0
- Deal price
- 1.25
- Shares
- 11999020
- Offering price
- $1.25
Registration 333-286670
- Gross proceeds
- 11999341.0
- Net proceeds
- 11099341.0
- Deal price
- 4.5
- Shares
- 2666520
- Offering price
- $4.50
- Ticker
- BCTXW
Registration 333-286735
- Gross proceeds
- 11999341.0
- Net proceeds
- 11099341.0
- Deal price
- 4.5
- Shares
- 2666520
- Offering price
- $4.50
- Ticker
- BCTXW
Filing attachments
ex99-1.htm · 8-K · 2026-06-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BRIAPRO THERAPEUTICS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTH PERIOD ENDED APRIL 30, 2026 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unaudited Condensed Interim Consolidated Financial Statements of BriaPro Therapeutics Corp. for the three and nine month periods ended April 30, 2026 and 2025 have been prepared by management in accordance with Internation…
Read attachment ↗ex99-2.htm · 8-K · 2026-06-26
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 BRIAPRO THERAPEUTICS CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended April 30, 2026 (Expressed in U.S. Dollars) The following Management’s Discussion and Analysis (“MD&A”) for BRIAPRO THERAPEUTICS CORP. (“BriaPro” or the “Company”) is prepared as of June 26, 2026 and relates to the unaudited condensed interim financial condition and results of operations of the Company for the three and nine month period ended Apri…
Read attachment ↗ex4-1.htm · 8-K · 2026-06-03
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 FORM OF PLACEMENT AGENT’S WARRANT BRIACELL THERAPEUTICS CORP. Warrant Shares: _____ Initial Exercise Date: June 2, 2026 THIS WARRANT TO PURCHASE COMMON SHARES (the “ Warrant ”) certifies that, for value received, ________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 2, 2026 (the “ Initial Exercise Date ”) and, in accordanc…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-03
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 BriaCell Therapeutics Announces Pricing of Offering Philadelphia & Vancouver, British Columbia - May 31, 2026 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.2…
Read attachment ↗ex99-2.htm · 8-K · 2026-06-03
EX-99.2 6 ex99-2.htm EX-99.2 Exhibit 99.2 BriaCell Therapeutics Announces Closing of Offering Philadelphia & Vancouver, British Columbia - June 2, 2026 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the closing of its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 p…
Read attachment ↗ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 BRIAPRO THERAPEUTICS CORP. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2026 (Unaudited) (Expressed in United States Dollars) NOTICE TO SHAREHOLDERS The accompanying Unaudited Condensed Interim Consolidated Financial Statements of BriaPro Therapeutics Corp. for the three and six month periods ended January 31, 2026 and 2025 have been prepared by management in accordance with Internati…
Read attachment ↗